The result comes 18 months after omecamtiv put in an underwhelming performance in the GALACTIC-HF trial, when Cytokinetics was partnering the drug with Amgen. That study actually met its primary ...
The filing was based mainly on the results of the GALACTIC-HF study, which met its primary objective of reducing cardiovascular death or heart failure events compared with placebo in HFrEF ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback